Notice: This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends EDGE vs. ACRS, NLTX, CYBN, ACRV, LXRX, SCPH, SLN, LYEL, NKTR, and ADCTShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Aclaris Therapeutics (ACRS), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Acrivon Therapeutics (ACRV), Lexicon Pharmaceuticals (LXRX), scPharmaceuticals (SCPH), Silence Therapeutics (SLN), Lyell Immunopharma (LYEL), Nektar Therapeutics (NKTR), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector. Edge Therapeutics vs. Aclaris Therapeutics Neoleukin Therapeutics Cybin Acrivon Therapeutics Lexicon Pharmaceuticals scPharmaceuticals Silence Therapeutics Lyell Immunopharma Nektar Therapeutics ADC Therapeutics Aclaris Therapeutics (NASDAQ:ACRS) and Edge Therapeutics (NASDAQ:EDGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Is ACRS or EDGE more profitable? Edge Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -136.65%. Aclaris Therapeutics' return on equity of -40.26% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Edge Therapeutics N/A -81.29%-56.92% Does the MarketBeat Community prefer ACRS or EDGE? Aclaris Therapeutics received 207 more outperform votes than Edge Therapeutics when rated by MarketBeat users. However, 66.79% of users gave Edge Therapeutics an outperform vote while only 66.67% of users gave Aclaris Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38466.67% Underperform Votes19233.33% Edge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Which has more risk and volatility, ACRS or EDGE? Aclaris Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Edge Therapeutics has a beta of 3.65, indicating that its stock price is 265% more volatile than the S&P 500. Do analysts rate ACRS or EDGE? Aclaris Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 328.02%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, ACRS or EDGE? Edge Therapeutics has lower revenue, but higher earnings than Aclaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$27.08M6.78-$88.48M-$0.52-4.94Edge TherapeuticsN/AN/A-$40.86MN/AN/A Do institutionals and insiders believe in ACRS or EDGE? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Edge Therapeutics shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by insiders. Comparatively, 37.1% of Edge Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor ACRS or EDGE? In the previous week, Aclaris Therapeutics had 2 more articles in the media than Edge Therapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 0 mentions for Edge Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.14 beat Edge Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aclaris Therapeutics Positive Edge Therapeutics Neutral SummaryAclaris Therapeutics beats Edge Therapeutics on 11 of the 16 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.80M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / BookN/A6.055.314.79Net Income-$40.86M$154.90M$122.54M$224.99M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/AN/AN/AN/A$43.80MN/A0.00N/AGap UpACRSAclaris Therapeutics4.0912 of 5 stars$2.50+0.8%$11.00+340.0%+125.4%$178.58M$27.08M-4.81100Short Interest ↑High Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.81-3.9%N/A-44.8%$176.78MN/A-6.0590High Trading VolumeCYBNCybin2.9361 of 5 stars$8.83-0.8%$138.00+1,462.9%N/A$176.53MN/A-1.3350Positive NewsACRVAcrivon Therapeutics1.7697 of 5 stars$5.56+0.9%$23.67+325.7%+32.9%$173.12MN/A-2.0658Short Interest ↑News CoverageLXRXLexicon Pharmaceuticals1.782 of 5 stars$0.69-2.0%$6.00+767.2%-46.9%$170.37M$5.23M-0.92140SCPHscPharmaceuticals3.3354 of 5 stars$3.38-3.7%$15.00+343.8%-38.6%$169.14M$30.28M-1.7830SLNSilence Therapeutics2.1074 of 5 stars$5.61-4.9%$57.20+919.6%-72.2%$167.90M$16.25M-3.57100LYELLyell Immunopharma2.2103 of 5 stars$0.57-3.2%$1.00+74.1%-69.7%$167.85M$63,000.00-0.73270High Trading VolumeNKTRNektar Therapeutics4.312 of 5 stars$0.90-6.4%$4.08+353.7%+66.8%$166.01M$93.14M-1.07220ADCTADC Therapeutics2.189 of 5 stars$1.72-0.3%$8.00+366.5%-0.3%$165.82M$70.72M-0.72310Negative News Related Companies and Tools Related Companies Aclaris Therapeutics Competitors Neoleukin Therapeutics Competitors Cybin Competitors Acrivon Therapeutics Competitors Lexicon Pharmaceuticals Competitors scPharmaceuticals Competitors Silence Therapeutics Competitors Lyell Immunopharma Competitors Nektar Therapeutics Competitors ADC Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDGE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
